LBRX LB PHARMACEUTICALS INC
Price Chart
Executive Summary
Zachary Prensky, a former officer of LB Pharmaceuticals, filed a Form 144 notice of intent to sell 16,500 shares of common stock, with an estimated aggregate market value of approximately $486,566. The sale is planned for June 9, 2026, via Stifel Nicolaus & Company. While the filing signals insider intent to sell, the relatively small size relative to the company's $843M market cap and the seller's status as a former officer reduce the signal's materiality.
Actionable Insight
The Form 144 is a routine advance notice of a small sale by a former officer. Given the minimal size relative to market cap and the insider's non-executive status, the filing is unlikely to have a material impact on the stock. Monitor for any subsequent Form 4 filings to confirm execution, but no immediate trading action is warranted.
Key Facts
- Insider Zachary Prensky (former officer) filed Form 144 to sell 16,500 shares.
- Estimated aggregate market value of the proposed sale: ~$486,566.
- Sale is planned for June 9, 2026, via Stifel Nicolaus & Company.
- Shares were acquired on September 12, 2025, and are held directly.
- The sale represents a small fraction of the company's $843M market cap.
Financial Impact
Proposed sale of ~$486,566 worth of shares, representing ~0.06% of market cap.
Risk Factors
- Insider sale could be perceived negatively if followed by additional insider selling.
- The filing is only an intent to sell; the actual sale may not occur.
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001972481-26-000189 |
| Document: 0001972481-26-000189-index.html | 0001972481-26-000189 |
| Document: 0001972481-26-000189.txt | 0001972481-26-000189 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
2d ago
|
8-K
| $28.41 awaiting T+5 | awaiting T+5 | — | $28.42 (+0.04%) |
|
Jun 9, 2026
3d ago
|
144
| $29.24 awaiting T+5 | awaiting T+5 | — | $28.42 (−2.80%) |
|
May 12, 2026
4w ago
|
Press Release
| $32.31 $27.27 | ▼ −15.60% | ▼ −14.44% | $28.42 (−12.04%) |
|
Apr 23, 2026
7w ago
|
DEFA14A
| $30.73 $31.71 | ▲ +3.19% | ▲ +2.28% | $28.42 (−7.52%) |
|
Apr 22, 2026
7w ago
|
Press Release
| $30.78 $30.59 | ▼ −0.60% | ▼ −2.08% | $28.42 (−7.65%) |
|
Apr 15, 2026
8w ago
|
EFFECT
| $29.12 $31.78 | ▲ +9.13% | ▲ +7.50% | $28.42 (−2.40%) |
|
Mar 26, 2026
11w ago
|
Press Release
| $23.84 $26.94 | ▲ +13.00% | ▲ +9.14% | $28.42 (+19.21%) |
|
Mar 25, 2026
11w ago
|
Press Release
| $24.21 $24.81 | ▲ +2.48% | ▲ +2.72% | $28.42 (+17.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access